KRAS and lung carcinoma: Using both a KRAS G12D genetically engineered mouse model of lung cancer and xenografting of CT26 mouse colon cancer cells, it was shown that genetic depletion or pharmacological targeting of fibroblast activation protein (FAP)-expressing cells decreased myofibroblasts content and impacted blood vessel density and extracellular matrix composition, ultimately inhibiting tumor cell proliferation/growth [81].